The U.S. Food and Drug Administration (FDA) may postpone the decision of authorizing the emergency use of newcrown vaccine under nvax.us to review the changes in the production process. Affected by this news, as of press time, Novax pharmaceutical fell 5.49% to $47.36 before the US market on Thursday.
Access:
An FDA spokesman said on Wednesday that Novax notified the agency of the changes in the production process of its new crown vaccine on June 3. The agency needs to review these changes before approving the emergency use authorization of its new crown vaccine in the United States. "FDA will carefully review any additional information submitted by the company as part of its ongoing evaluation," the spokesman said
It is reported that just yesterday, the FDA independent vaccine expert committee, after reviewing the data on the safety and effectiveness of Novavax's new coronavirus vaccine in preventing novel coronavirus, voted overwhelmingly to approve the use of the new coronavirus vaccine in the United States. Although FDA usually follows the committee's recommendations, the agency is not obliged to do so.